These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 238357)

  • 1. The bioavailability of a new sustained-released preparation of proxiphylline (Neofylin Retard)in the guinea pig.
    Larsen JJ
    Acta Pharmacol Toxicol (Copenh); 1975 Aug; 37(2):113-20. PubMed ID: 238357
    [No Abstract]   [Full Text] [Related]  

  • 2. Animal pharmacology of the selective histamine H1-receptor antagonist tazifylline.
    Poizot A; Dumez D; Ferrandon P; Lefournier C; Michel A; Armstrong JM
    Arzneimittelforschung; 1986 Apr; 36(4):695-702. PubMed ID: 2424463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bioavailability of 3 theophylline delayed-release preparations. Comparison of theophylline concentrations in the serum and saliva in the steady state].
    Bochsler HP; Meyer UA
    Schweiz Med Wochenschr; 1982 Nov; 112(47):1702-10. PubMed ID: 7178872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparative subacute study of the effects and side effects of a non-depot theophylline preparation (Euspirax) and a depot preparation (Euphyllin retard)--a contribution to long-term therapy of asthma].
    Eitner L; Wettengel R; Schnitker J
    Prax Klin Pneumol; 1983 Jun; 37(6):236-42. PubMed ID: 6889277
    [No Abstract]   [Full Text] [Related]  

  • 5. [Experimental research on the anti-asthmatic action of morpholino-methyl-theophylline].
    Vertua R; Caffau S
    Clin Ter; 1967 Sep; 42(5):407-19. PubMed ID: 4389841
    [No Abstract]   [Full Text] [Related]  

  • 6. [Bioavailability of theophylline in a new oral sustained-release preparation (author's transl)].
    Schneider GF; Heese GU; Huber HJ; Janzen N; Jünger H; Moser C; Stanislaus F
    Arzneimittelforschung; 1981; 31(9):1489-97. PubMed ID: 7197962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses.
    Schuppan D; Molz KH; Staib AH; Rietbrock N
    Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):223-7. PubMed ID: 7251238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biological availability of potassium from a sustained release preparation].
    Müller A; Thoma M; Renker H
    Schweiz Med Wochenschr; 1976 Jan; 106(1):27-30. PubMed ID: 1251146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative bioavailability of 2 oral theophylline sustained-release preparations].
    Tritthart W; Lücker PW; Fáy E; Buchebner J
    Arzneimittelforschung; 1983; 33(11):1603-6. PubMed ID: 6686457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bioavailability of theophylline after oral administration of a retard preparation of theophylline-ethylenediamine and the influence of 15-day ingestion on elimination kinetics after i.v. injection (author's transl)].
    Wiessmann KJ
    Arzneimittelforschung; 1980; 30(2):329-32. PubMed ID: 7378114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic action of a drug with constant and prolonged release (Netaprina Dospan) in the treatment of various obstructive broncho-pneumopathies].
    Fontana A; Ballerini G
    Policlinico Prat; 1970 Sep; 77(39):1247-54. PubMed ID: 4394634
    [No Abstract]   [Full Text] [Related]  

  • 12. [Absolute bioavailability of theophylline (Euphylline)].
    Somogyi A; Gugler R
    Fortschr Med; 1980 Nov; 98(43):1707-10. PubMed ID: 7450653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New pharmacological data on the bronchospasmolytic activity of bamifylline.
    Berti F; Magni F; Rossoni G; Schiantarelli P; Bongrani S; Pasargiklian R
    Arzneimittelforschung; 1988 Jan; 38(1):40-4. PubMed ID: 3365275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical experimentation with spirometric control of an antiasthmatic preparation with delayed action].
    Basevi A; Cielo R; Tison M
    Clin Ter; 1966 Feb; 36(4):302-12. PubMed ID: 4380155
    [No Abstract]   [Full Text] [Related]  

  • 15. Metabolism of 7-(1,3-thiazolidin-2-ylmethyl)theophylline by rat liver microsomes. Evidence for a monooxygenase-dependent step in 1,3-thiazolidine ring cleavage.
    Grosa G; Caputo O; Ceruti M; Biglino G
    Drug Metab Dispos; 1992; 20(5):742-6. PubMed ID: 1358581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Absorption profile and absolute bioavailability of a theophylline--retard preparation].
    Pabst G; Weber W; Barkworth MF; Müller M; Rehm KD
    Arzneimittelforschung; 1990 Nov; 40(11):1218-24. PubMed ID: 2085333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absorption of sustained-release theophylline tablets.
    Fagerström PO; Heintz L
    Int J Clin Pharmacol Ther Toxicol; 1983 Jul; 21(7):359-62. PubMed ID: 6885207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacokinetics and biologic availability of a new theophylline sustained-release preparation].
    Brüller W; Fischer M; Tritthart W
    Arzneimittelforschung; 1985; 35(12):1854-9. PubMed ID: 4096745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of aminophylline and theophylline sustained-release formulations by their bioavailability and steady-state serum levels.
    Steinijans VW; Zech K; Fischer R
    Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):624-30. PubMed ID: 6668100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antianaphylactic and antiasthmatic properties of new piperazinyl 7-(beta-hydroxypropyl)-theophylline derivatives in guinea pigs.
    Czarnecki R; Librowski T; Pawłowski M
    Pol J Pharmacol; 2001; 53(2):131-6. PubMed ID: 11787952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.